We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

5 hedge funds and large institutions have $2.58M invested in Blueprint Medicines in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 344 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

99% less funds holding

Funds holding: 354 → 5 (-349)

99.54% less ownership

Funds ownership: 99.58% → 0.04% (-100%)

100% less capital invested

Capital invested by funds: $8.24B → $2.58M (-$8.24B)

100% less funds holding in top 10

Funds holding in top 10: 29 → 0 (-29)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 344

Holders
5
Holders Change
-349
Holders Change %
-98.59%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
-29
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
1
Reduced
3
Closed
344
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IA
IFP Advisors
Florida
+$2.06K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$822M
2
BlackRock
BlackRock
New York
-$784M
3
PCM
Pentwater Capital Management
Florida
-$500M
4
State Street
State Street
Massachusetts
-$286M
5
UBS Group
UBS Group
Switzerland
-$278M
Name Holding Trade Value Shares
Change 		Change in
Stake
PWMG
326
Private Wealth Management Group
New Jersey
– -$6.28K -49 Closed
WA
327
WPG Advisers
Maryland
– -$5.77K -45 Closed
HWP
328
Highline Wealth Partners
California
– -$5.38K -42 Closed
AssetMark Inc
329
AssetMark Inc
California
– -$5.13K -40 Closed
MPWT
330
MassMutual Private Wealth & Trust
Connecticut
– -$3.97K -31 Closed
BIG
331
Brooklyn Investment Group
New York
– -$3.08K -24 Closed
CTC
332
Central Trust Company
Missouri
– -$2.95K -23 Closed
GWM
333
Geneos Wealth Management
Colorado
– -$2.95K -23 Closed
RAM
334
Riggs Asset Management
Pennsylvania
– -$2.82K -22 Closed
WWM
335
Wolff Wiese Magana
California
– -$2.44K -19 Closed
MAM
336
Meeder Asset Management
Ohio
– -$2.31K -18 Closed
LSA
337
Leonteq Securities AG
Switzerland
– -$1.54K -12 Closed
OP
338
ORG Partners
Indiana
– -$1.41K -11 Closed
Jones Financial Companies
339
Jones Financial Companies
Missouri
– -$1.15K -9 Closed
MCM
340
MAI Capital Management
Ohio
– -$1.15K -9 Closed
PWA
341
Physician Wealth Advisors
Utah
– -$1.15K -9 Closed
BF
342
BOK Financial
Oklahoma
– -$1.02K -8 Closed
SS
343
SBI Securities
Japan
– -$641 -5 Closed
CIBC Private Wealth Group
344
CIBC Private Wealth Group
Georgia
– -$513 -4 Closed
NA
345
NewEdge Advisors
Louisiana
– -$513 -4 Closed
LFG
346
Larson Financial Group
Missouri
– -$385 -3 Closed
CWP
347
Concord Wealth Partners
Virginia
– -$128 -1 Closed
TFA
348
Transamerica Financial Advisors
Florida
– -$78 -1 Closed
10 11 12 13
14

BPMC Hedge Fund Activity: Q3 2025 in Review

5 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2025, worth a combined $2.58M — down 100% from $8.24B a quarter earlier.

Sellers outnumbered buyers: 344 funds closed out of BPMC and 0 opened new positions — a net loss of 344 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was IFP Advisors, adding an estimated $2.06K. The largest seller was Vanguard Group, exiting entirely with an estimated $822M sold.

  • 5 institutional investors held Blueprint Medicines (BPMC) as of Q3 2025, down from 354 in Q2 2025.
  • Funds reported $2.58M of Blueprint Medicines stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Blueprint Medicines positions in Q3 2025 and 344 closed out, a net change of -344 holders.
  • The largest Blueprint Medicines buyer in Q3 2025 was IFP Advisors, an estimated $2.06K added.
  • The largest Blueprint Medicines seller in Q3 2025 was Vanguard Group, an estimated $822M sold.

Based on aggregated 13F filings for Q3 2025.